<DOC>
	<DOCNO>NCT00352495</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinblastine carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vinblastine give together carboplatin treat young patient newly diagnose recurrent low-grade glioma .</brief_summary>
	<brief_title>Vinblastine Carboplatin Treating Young Patients With Newly Diagnosed Recurrent Low-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate maximum tolerate dose recommended phase II dose vinblastine give combination carboplatin pediatric patient newly diagnose recurrent low-grade glioma . - Define describe acute dose-limiting toxicity regimen . - Describe toxicity associate repeated course combination chemotherapy regimen number treatment modification require course treatment . Secondary - Describe radiographic response patient treat regimen . - Describe change diffusion/perfusion image study therapy . OUTLINE : This multicenter , dose-escalation study vinblastine . Patients stratify accord amount prior therapy ( heavily pretreated v less heavily pretreated ) . Patients receive carboplatin IV 30 minute day 1 vinblastine IV day 1 , 8 , 15 . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos vinblastine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow 30 day . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* lowgrade glioma , include 1 follow subtypes : Astrocytoma variant Fibrillary , protoplasmic , mixed Pilocytic astrocytoma , include pilomyxoid variant Pleomorphic xanthoastrocytoma Infantile desmoplastic astrocytoma Ganglioglioma Oligodendroglial tumor Mixed glioma , include oligoastrocytoma NOTE : *Biopsy require patient visual pathway tumor involve optic nerve and/or optic radiation ( i.e. , isolated hypothalamus/chiasm ) Biopsy proven focal lowgrade glioma brainstem measurable disease allow No diffuse , intrinsic brainstem tumor Residual tumor visible MRI Patients without NF1 must meet following criterion : Progressive disease surgery/biopsy base clear radiographic clinical evidence progression OR gross residual tumor ( &gt; 1.5 cm² ) surgery/biopsy felt high risk patient neurologic and/or visual impairment tumor progress Visual pathway tumor isolate hypothalamus/chiasm biopsied must high risk patient neurologic and/or visual impairment Patients NF1 must evidence radiographic progression MRI and/or clinical worsening ( e.g. , worsen ophthalmologic exam visual pathway tumor ) Meets 1 follow criterion : Newly diagnose disease Recurrent disease No ventriculoperitoneal shuntrelated ascites PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( patient &gt; 10 year age ) OR Lansky PS 50100 % ( patient ≤ 10 year age ) Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( RBC transfusion allow ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine base age , follow : No great 0.8 mg/dL ( patient ≤ 5 year age ) No great 1.0 mg/dL ( patient 610 year age ) No great 1.2 mg/dL ( patient 1115 year age ) No great 1.5 mg/dL ( patient &gt; 15 year age ) Bilirubin ≤ 1.5 time upper limit normal ALT ≤ 110 U/L Albumin ≥ 2 g/dL No history allergy carboplatin No hyponatremia require treatment No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior therapy except corticosteroid surgery ( patient newly diagnose disease ) Prior chemotherapy and/or radiotherapy addition surgery corticosteroid allow ( patient recurrent disease ) Prior carboplatin and/or vinblastine allow evidence progressive disease therapy dose reduction due toxicity ( patient recurrent disease ) At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) recover ( patient recurrent disease ) At least 7 day since prior hematopoietic growth factor ( patient recurrent disease ) At least 7 day since prior biological agent ( patient recurrent disease ) At least 9 month since prior external beam radiotherapy gamma knife therapy include target lesion ( i.e. , restriction new lesion arises outside radiation field nonirradiated lesion progress ) recover ( patient recurrent disease ) No concurrent investigational drug No concurrent anticancer agents No concurrent chemotherapy , radiotherapy , immunotherapy , biological therapy No concurrent corticosteroid antiemesis Concurrent steroid allow tumor edema/increased intracranial pressure provide dose dexamethasone stable decrease past 7 day Concurrent physiologic stress dos steroids allow endocrine deficiency</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>neurofibromatosis type 1</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
</DOC>